505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Annual Report to Security Holders
Artelo Biosciences Enters At The Market Offering Agreement for $6.53M
Termination of At-The-Market Offering Agreement with R.F. Lafferty
Regains Compliance with Nasdaq Listing Requirements
Announces Closing of $11.0 Million Private Placement
Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
Artelo Biosciences Enters into $337,300 Securities Purchase Agreements
Reports on Financial Statements and Going Concern Matter
Q1
FY 2024
Q3
Q2
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
S-1
Additional Proxy Materials
PRER14A
Definitive Proxy Statement
PRE 14A
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence